Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company.

・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...

The healthcare giant has been investing heavily in its future growth.

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...

Pfizer is making more changes to its layout in California by stepping away from a South San Francisco office site that used ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Despite trading near decade-low valuations, Pfizer (NYSE:PFE) is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

The healthcare stock looks ridiculously undervalued.

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it’s acquiring Metsera, and its portfolio of four medications ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Find the latest pfizer vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...